Search details
1.
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Oncologist
; 26(1): e164-e172, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33017510
2.
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Oncologist
; 26(2): 139-146, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33145877
3.
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.
Oncologist
; 23(6): 740-745, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29438093
4.
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Oncologist
; 23(3): 353-359, 2018 03.
Article
in English
| MEDLINE | ID: mdl-29242281
5.
State of the Science and Future Directions for Liquid Biopsies in Drug Development.
Oncologist
; 25(9): 730-732, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32510742
6.
Development, Validation, and Regulatory Considerations for a Liquid Biopsy Test.
Clin Chem
; 66(3): 408-414, 2020 03 01.
Article
in English
| MEDLINE | ID: mdl-32091082
7.
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 42(15): 1851-1860, 2024 May 20.
Article
in English
| MEDLINE | ID: mdl-38452327
8.
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 42(5): 605-613, 2024 Feb 10.
Article
in English
| MEDLINE | ID: mdl-38127780
9.
Regulatory implications of ctDNA in immuno-oncology for solid tumors.
J Immunother Cancer
; 11(2)2023 02.
Article
in English
| MEDLINE | ID: mdl-36796877
10.
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Clin Cancer Res
; 29(17): 3262-3266, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37022784
11.
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Clin Cancer Res
; 29(3): 508-512, 2023 02 01.
Article
in English
| MEDLINE | ID: mdl-36112541
12.
Characterization of whole genome amplified (WGA) DNA for use in genotyping assay development.
BMC Genomics
; 13: 217, 2012 Jun 01.
Article
in English
| MEDLINE | ID: mdl-22655855
13.
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
J Clin Oncol
; 40(11): 1155-1162, 2022 04 10.
Article
in English
| MEDLINE | ID: mdl-35084948
14.
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
Clin Cancer Res
; 28(6): 1058-1071, 2022 03 15.
Article
in English
| MEDLINE | ID: mdl-34711631
15.
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
Clin Cancer Res
; 28(6): 1072-1086, 2022 03 15.
Article
in English
| MEDLINE | ID: mdl-34711632
16.
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Clin Cancer Res
; 28(2): 249-254, 2022 01 15.
Article
in English
| MEDLINE | ID: mdl-34344795
17.
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
JCO Precis Oncol
; 6: e2100372, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35952319
18.
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.
JCO Precis Oncol
; 6: e2200454, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36446042
19.
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.
Clin Cancer Res
; 27(17): 4685-4689, 2021 09 01.
Article
in English
| MEDLINE | ID: mdl-34083238
20.
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.
Clin Cancer Res
; 27(8): 2126-2129, 2021 04 15.
Article
in English
| MEDLINE | ID: mdl-33188141